Premium
Impaired chronic pain‐like behaviour and altered opioidergic system in the TASTPM mouse model of Alzheimer's disease
Author(s) -
Aman Y.,
Pitcher T.,
Ballard C.,
Malcangio M.
Publication year - 2019
Publication title -
european journal of pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.305
H-Index - 109
eISSN - 1532-2149
pISSN - 1090-3801
DOI - 10.1002/ejp.1288
Subject(s) - opioidergic , medicine , allodynia , chronic pain , analgesic , gabapentin , osteoarthritis , opioid , morphine , opioid antagonist , (+) naloxone , anesthesia , nociception , hyperalgesia , physical therapy , pathology , receptor , alternative medicine
Background Chronic pain conditions, especially osteoarthritis (OA), are as common in individuals with Alzheimer's disease ( AD ) as in the general elderly population, which results in detrimental impact on patient's quality of life. However, alteration in perception of pain in AD coupled with deteriorating ability to communicate pain sensations often result in under‐diagnosis and inappropriate management of pain. Therefore, a better understanding of mechanisms in chronic pain processing in AD is needed. Here, we explored the development and progression of OA pain and the effect of analgesics in a transgenic mouse model of AD . Methods Unilateral OA pain was induced chemically, via an intra‐articular injection of monosodium iodoacetate ( MIA ) in the left knee joint of AD ‐mice ( TASTPM ) and age‐ and gender‐matched C57 BL /6J ( WT ). Pharmacological and biochemical assessments were conducted in plasma and spinal cord tissue. Results MIA resulted in hind paw mechanical hypersensitivity (allodynia), initiating on day 3, in TASTPM and WT controls. However, from 14 to 28 days, TASTPM displayed partial attenuation of allodynia and diminished spinal microglial response compared to WT controls. Naloxone, an opioid antagonist, re‐established allodynia levels as observed in the WT group. Morphine, an opioid agonist, induced heightened analgesia in AD ‐mice whilst gabapentin was devoid of efficacy. TASTPM exhibited elevated plasma level of β‐endorphin post‐ MIA which correlated with impaired allodynia. Conclusions These results indicate an alteration of the opioidergic system in TASTPM as possible mechanisms underlying impaired persistent pain sensitivity in AD . This work provides basis for re‐evaluation of opioid analgesic use for management of pain in AD . Significance This study shows attenuated pain‐like behaviour in a transgenic mouse model of Alzheimer's disease due to alterations in the opioidergic system and central plasticity mechanisms of persistent pain.